血清降钙素原在社区获得性肺炎诊治中的临床应用价值

doi:10.13481/j.1671-587x.20150229

Abstract

Abstract:

Objective To detect the level of serum procalcitonin(PCT) in the patients with community acquired pneumonia(CAP),and to clarify its significance in diagnosis and treatment of CAP.Methods 127 CAP patients and 30 cases of normal individuals were selected. According to the sputum bacterial culture results,127 CAP patients were divided into positive bacteria culture group (n=54)and negative bacteria culture group (n=73);according to the diagnostic criteria of severe pneumonia,the bacteria culture positive group was divided into severe pneumonia group (n=13) and non-severe pneumonia group(n=41). The levels of serum PCT,the white blood cell (WBC) count,neutrophil percentage(NEUT%) and levels of C-reactive protein (CRP) of the objects were detected by double antibody sandwich method.Results After treated for 8 d,the levels of serum PCT of the objects in positive bacteria culture group and negative bacteria culture group and normal control group had no significant differences. After treated for 8 d, the levels of serum PCT of the objects in positive bacteria culture group and negative bacteria culture group were lower than that of the objects on the first day after treatment.The level of serum PCT of the patients in severe pneumonia group was significantly higher than that in non-severe pneumonia group;the WBC count,NEUT% and CRP level of the patients in severe pneumonia group were higher than those in non-severe pneumonia group,but the difference was not statistically significant. When consindering the bacterial culture as the gold standard for diagnosis of bacterial infection,the sensitivity and specificity of the serum level in diagnosis of bacterial CAP were superior to NEUT% and WBC count.Conclusion The level of serum PCT plays a role in the diagnosis of CAP,and it could help to judge whether the CAP patient gets a bacterial infection and assess the severity of pneumonia and the discontinuation of antibiotics.

Key words: community acquired pneumonia, procalcitonin, white blood cell count, neutrophil percentage, C-reactive protein

CLC Number:

R563.1

LI Ning, SUN Wenwei, ZHAO Jianjun, TAN Ping, WANG Jing. Clinical value of serum procalcitonin in diagnosis and treatment of community acquired pneumonia[J].Journal of Jilin University Medicine Edition, 2015, 41(02): 352-355.

References

[1] Schuetz P, Albrich WC,Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions[J].BMC Med,2011,9:107.doi:10.1186/1471-7015-9-107.

[2] Ruiz-Rodríguez J,Rello J. Predicting treatment failure in severe sepsis and septic shock[J]. Crit Care,2013,17(5):180.doi:10.1186/cc12877.

[3] Schuetz P,Maurer P,Punjabi V,et al. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients[J]. Crit Care,2013,17(3):R115.

[4] 降钙素原急诊临床应用专家共识组.降钙素原急诊临床应用的专家共识[J].中华急诊医学杂志,2012,21(9):944-951.

[5] 中华医学会呼吸病学分会. 社区获得性肺炎诊断和治疗指南[J]. 中华结核和呼吸杂志, 2006, 29(10):651-655.

[6] 何礼贤.降钙素原指导严重细菌感染和脓毒血症诊疗的临床意义[J].中华结核和呼吸杂志,2012,35(8):636-637.

[7] Jekarl DW,Lee SY,Lee J,et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis[J]. Diagn Microbiol Infect Dis,2013,75(4):342-347.

[8] Krüger S,Ewig S,Marre R,et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes [J]. Eur Respir J,2008,31(2):349-355.

[9] Espaa PP,Capelastegui A,Bilbao A,et al. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia [J]. Eur J Clin Microbiol Infect Dis,2012,31(12):3397-3405.

[10] Nyamande K,Lalloo UG.Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP [J].Int J Tuberc Lung Dis,2006,10(5):510-515.

[11] Huang DT,Weissfeld LA,Kellum JA,et al.Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia [J].Ann Emerg Med, 2008,52(1):48-58.

[12] Johansson N,Kalin M,Backman-Johansson C,et al. Procalcitonin levels in community-acquired pneumonia correlation with aetiology and severity[J]. Scand J Infect Dis,2014,46(11):787-791.

[13] Park JH,Wee JH,Choi SP,et al.The value of procalcitonin level in community-acquired pneumonia in the ED[J].Am J Emerg Med,2012,30 (7):1248-1254.

[14] Kim JH,Seo JW,Mok JH,et al.Usefulness of plasma procalcitonin to predict severity in elderly patients in community-acquired pneumonia [J]. Tuberc Respir Dis (Seoul),2013,74 (5):207-214.

[15] Woodhead M,Blasi F,Ewig S,et al.Guidelines for the management of adult lower respiratory tract infections[J].Clin Microbiol Infect,2011,17(Suppl 6):E1-E59.

[16] Schuetz P,Briel M,Mueller B,et al. Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections [J].JAMA,2013,309(7):717-718.

[17] Stolz D,Christ-Crain M,Bingisser R,et al. Antibiotic treatment of exacerbations of COPD:a randomized,controlled trial comparing procalcitonin guidance with standard therapy[J].Chest,2007,131(1):9-19.

[18] Fazili T,Endy T,Javaid W,et al. Role of procalcitonin in guiding antibiotic therapy[J]. Am J Health Syst Pharm,2012,69 (23):2057-2061.

[19] Albrich WC,Dusemund F,Bucher B,et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life":an international,multicenter post study survey (ProREAL) [J]. Arch Intern Med,2012,172 (9):715-722.

[20] Schuetz P,Chiappa V,Briel M,et al. Procalcitonin algorithms for anti-biotic therapy decisions:a systematic review of randomized controlled trials and recommendations for clinical algorithms[J].Arch Intern Med,2011,171(15):1322-1271.

[21] 郭娟,陈国勇,杨霄,等. 血清降钙素原水平在肝移植术后并发肺部感染患者中的诊断价值[J].中国老年学杂志,2014,34(22):6245-6247.

[22] 蔡川奇,林志鸿,蔺佩鸿,等.血清白蛋白和前白蛋白对老年肺炎病情的预测价值[J].中国老年学杂志,2014,34(1):103-105.

Clinical value of serum procalcitonin in diagnosis and treatment of community acquired pneumonia

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Metrics

Comments

Recommended 0

[1]	LIU Yan,WANG Lei,LIN Chong-tao,REN Chun-xia,DING Zi-qing,TANG Yu-xin,YU Hai-jiao. Detection of serum levels of hypersensitivity C-reactive  protein in patients with essential hypertension and  periodontitis and clinical significance [J]. Journal of Jilin University Medicine Edition, 2013, 39(4): 795-799.
[2]	JIAO Hai-xu,ZHANG Ming-qiu,ZHAO Jin-yan\|CHEN Xiao-shuai. Evaluation on curative effect of azelnidipine on hypertensionand its inhibitory effect on atherosclerosis [J]. J4, 2012, 38(4): 736-740.
[3]	CHENG Hong-ling, PENG Peng, ZHU Rong, QIN Yong-sheng. Effects of eight weeks exercise prescription intervention on aerobic capacity, body composition, blood lipid and C-reactive protein in obese adolescents [J]. J4, 2012, 38(4): 745-749.
[4]	LIU Ying\|LI Chun-yan\|SHAO Hai-feng\|LIANG Shuang. Analysis clinical effect of negative pressure \|drainage in treatment of acute periapical periodontitis [J]. J4, 2011, 37(2): 327-330.
[5]	YANG Wen, ZHANG Yan-Hua, SHA Chun-Rui. Changes of homocysteic acid and C-reactive protein levels in blood plasma of elderly patients with coronary heart disease and their clinical significances [J]. J4, 2009, 35(6): 1115-1118.
[6]	CHANG Ying,HAN Xue-mei,XING Ying,YANG Hong. Relationship between levels of serum CRP and cerebral thrombosisin patients with transient ischemia attack [J]. J4, 2008, 34(3): 489-491.
[7]	YANG Wen,SHA Chun-rui,LIU Bai-hui,ZHANG Yan-hua,LU He,YU Yan-chun,JI You-mei,XU Dan,XU Gui-ying. Detection of serum C-reactive protein,lipoprotein(a) and fibrinogen levels in elderly patients with acute cerebral infarction and clinical significance [J]. J4, 2007, 33(6): 1066-1069.
[8]	IN Ling, ZHAO Xue-zhong, ZHANG Zhi-guo, XUE Jian-hong. Changes in serum vascular cell adhesion molecules and C-reactive protein in patients with acute coronary syndrome [J]. J4, 2005, 31(5): 799-801.
[9]	HAN Xi-chun， Han Ning,ZHANG Ying-chao，WANG Yu，JIA Ming-kun. Changes of serum interleukin-10 and C-reactive protein in patients with acute pancreatitis [J]. J4, 2004, 30(5): 759-761.
[10]	QIN Ling, MA Jin-hui,LEI Yu. Level of C-reactive protein and effects of lipitor on C-reactiveprotein and lipids in patients with hyperlipidemia [J]. J4, 2004, 30(1): 114-116.